Literature DB >> 20466736

Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease.

Koichi Iijima1, Anthony Gatt, Kanae Iijima-Ando.   

Abstract

The amyloid-beta 42 (Abeta42) peptide has been suggested to promote tau phosphorylation and toxicity in Alzheimer's disease (AD) pathogenesis; however, the underlying mechanisms are not fully understood. Using transgenic Drosophila expressing both human Abeta42 and tau, we show here that tau phosphorylation at Ser262 plays a critical role in Abeta42-induced tau toxicity. Co-expression of Abeta42 increased tau phosphorylation at AD-related sites including Ser262, and enhanced tau-induced neurodegeneration. In contrast, formation of either sarkosyl-insoluble tau or paired helical filaments was not induced by Abeta42. Co-expression of Abeta42 and tau carrying the non-phosphorylatable Ser262Ala mutation did not cause neurodegeneration, suggesting that the Ser262 phosphorylation site is required for the pathogenic interaction between Abeta42 and tau. We have recently reported that the DNA damage-activated Checkpoint kinase 2 (Chk2) phosphorylates tau at Ser262 and enhances tau toxicity in a transgenic Drosophila model. We detected that expression of Chk2, as well as a number of genes involved in DNA repair pathways, was increased in the Abeta42 fly brains. The induction of a DNA repair response is protective against Abeta42 toxicity, since blocking the function of the tumor suppressor p53, a key transcription factor for the induction of DNA repair genes, in neurons exacerbated Abeta42-induced neuronal dysfunction. Our results demonstrate that tau phosphorylation at Ser262 is crucial for Abeta42-induced tau toxicity in vivo, and suggest a new model of AD progression in which activation of DNA repair pathways is protective against Abeta42 toxicity but may trigger tau phosphorylation and toxicity in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466736      PMCID: PMC2901137          DOI: 10.1093/hmg/ddq200

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  116 in total

Review 1.  Mushroom body memoir: from maps to models.

Authors:  Martin Heisenberg
Journal:  Nat Rev Neurosci       Date:  2003-04       Impact factor: 34.870

Review 2.  Live or let die: the cell's response to p53.

Authors:  Karen H Vousden; Xin Lu
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 3.  Transgenic animal models of tauopathies.

Authors:  Virginia M-Y Lee; Theresa K Kenyon; John Q Trojanowski
Journal:  Biochim Biophys Acta       Date:  2005-01-03

4.  Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.

Authors:  A Sengupta; J Kabat; M Novak; Q Wu; I Grundke-Iqbal; K Iqbal
Journal:  Arch Biochem Biophys       Date:  1998-09-15       Impact factor: 4.013

5.  Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding.

Authors:  Jae-Hyeon Cho; Gail V W Johnson
Journal:  J Biol Chem       Date:  2002-10-29       Impact factor: 5.157

6.  Tau is essential to beta -amyloid-induced neurotoxicity.

Authors:  Mark Rapoport; Hana N Dawson; Lester I Binder; Michael P Vitek; Adriana Ferreira
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

7.  Increased steady state mRNA levels of DNA-repair genes XRCC1, ERCC2 and ERCC3 in brain of patients with Down syndrome.

Authors:  S G Fang-Kircher; O Labudova; E Kitzmueller; H Rink; N Cairns; G Lubec
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

8.  Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model.

Authors:  Jennifer Drake; Christopher D Link; D Allan Butterfield
Journal:  Neurobiol Aging       Date:  2003 May-Jun       Impact factor: 4.673

9.  Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro.

Authors:  Mihaela Necula; Jeff Kuret
Journal:  J Biol Chem       Date:  2004-09-10       Impact factor: 5.157

10.  Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila.

Authors:  George R Jackson; Martina Wiedau-Pazos; Tzu-Kang Sang; Naveed Wagle; Carlos A Brown; Sasan Massachi; Daniel H Geschwind
Journal:  Neuron       Date:  2002-05-16       Impact factor: 17.173

View more
  43 in total

1.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

2.  Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated Aβ toxicity in Drosophila.

Authors:  Seongsoo Lee; Ji-Wu Wang; Wendou Yu; Bingwei Lu
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

3.  Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.

Authors:  Mohammad Arif; Jianshe Wei; Qi Zhang; Fei Liu; Gustavo Basurto-Islas; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

4.  Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.

Authors:  Hui Wei; Hui-Liang Zhang; Jia-Zhao Xie; Dong-Li Meng; Xiao-Chuan Wang; Dan Ke; Ji Zeng; Rong Liu
Journal:  Curr Med Sci       Date:  2020-03-13

5.  Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats.

Authors:  Wenqing Yang; Jing Ma; Zheng Liu; Yongliang Lu; Bin Hu; Huarong Yu
Journal:  Neurol Sci       Date:  2013-12-12       Impact factor: 3.307

6.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

7.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

8.  Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Authors:  Oyinkan Sofola; Fiona Kerr; Iain Rogers; Richard Killick; Hrvoje Augustin; Carina Gandy; Marcus J Allen; John Hardy; Simon Lovestone; Linda Partridge
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

Review 9.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 10.  Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.

Authors:  Yunpeng Huang; Zhihao Wu; Bing Zhou
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.